Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

European Medicines Agency Recommends Granting a Conditional Marketing Authorisation for Osimertinib

It is intended for the treatment of locally advanced or metastatic NSCLC associated with EGFR T790M
21 Dec 2015
Cytotoxic Therapy
Thoracic Malignancies

On 17 December 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product osimertinib (Tagrisso), intended for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) associated with EGFR T790M.

The applicant for this medicinal product is AstraZeneca AB.

A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorisation holder is likely to provide comprehensive clinical data at a later stage.

Tagrisso will be available as 40 mg and 80 mg film-coated tablets. The active substance of Tagrisso is osimertinib, a tyrosine kinase inhibitor - TKI (ATC code: L01XE35). Osimertinib is an irreversible inhibitor of epidermal growth factor receptors that harbour sensitizing mutations (EGFRm) and TKI-resistance mutation T790M.

The benefits with Tagrisso are its significant activity in patients with NSCLC harbouring the T790M mutation.

The most common side effects are diarrhoea and rash. The most common severe side effects are pneumonia, pulmonary embolism and dyspnoea.

The full indication is: "Tagrisso is indicated for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC)."

It is proposed that Tagrisso should be initiated by a physician experienced in the use of anticancer therapies.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Last update: 21 Dec 2015

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.